In view of the above facts, Met@Man-MP efficiently integrated all features to improve the therapeutic efficacy of anti-PD1 antibody, generating remarkable anticancer activity after coadministration in different tumor models, including H22 tumor-bearing mice, 4T-1 tumor-bearing mice, AOM/DSS-induced CAC mice, and even an organotypic ex vivo slice culture model of fresh human tumors. This evidence concerns the gene PDCD1 and neoplasm.